Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Idelalisib: targeting PI3Kδ in B-cell malignancies.

× No keyword cloud information.

8 in total

1. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.

Authors: Wenli Cui; Shutao Zheng; Xinxia Li; Yuqing Ma; Wei Sang; Ming Liu; Wei Zhang; Xiaoyan Zhou
Journal: Tumour Biol Date: 2016-07-22

Review 2. PI3K Targeting in Non-solid Cancer.

Authors: Hye Na Kim; Heather Ogana; Vanessa Sanchez; Cydney Nichols; Yong-Mi Kim
Journal: Curr Top Microbiol Immunol Date: 2022 Impact factor: 4.737

3. Targeted PI3Kδ inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma.

Authors: Tracy C Okoli; Cody J Peer; Kieron Dunleavy; William D Figg
Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742

Review 4. Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.

Authors: Ruifang Sun; Jinfen Wang; Ken H Young
Journal: Crit Rev Oncog Date: 2017

5. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.

Authors: Annalisa Lonetti; Alessandra Cappellini; Antonino Maria Spartà; Francesca Chiarini; Francesca Buontempo; Camilla Evangelisti; Cecilia Evangelisti; Ester Orsini; James A McCubrey; Alberto Maria Martelli
Journal: Oncotarget Date: 2015-04-30

Review 6. CAM-DR: Mechanisms, Roles and Clinical Application in Tumors.

Authors: Yuejiao Huang; Yuchan Wang; Jie Tang; Shiyi Qin; Xianjuan Shen; Song He; Shaoqing Ju
Journal: Front Cell Dev Biol Date: 2021-07-06

7. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K.

Authors: Carrie L Lucas; Yu Zhang; Anthony Venida; Ying Wang; Jason Hughes; Joshua McElwee; Morgan Butrick; Helen Matthews; Susan Price; Matthew Biancalana; Xiaochuan Wang; Michael Richards; Tamara Pozos; Isil Barlan; Ahmet Ozen; V Koneti Rao; Helen C Su; Michael J Lenardo
Journal: J Exp Med Date: 2014-12-08 Impact factor: 14.307

Review 8. Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.

Authors: Rui-Fang Sun; Qian-Qian Yu; Ken H Young
Journal: Chronic Dis Transl Med Date: 2018-03-12

8 in total